1. A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment. Issue 5 (8th November 2013) Authors: Laille, Eric; Goel, Sanjay; Mita, Alain C.; Gabrail, Nashat Y.; Kelly, Kevin; Liu, Liangang; Songer, Stephen; Beach, Charles L. Journal: Pharmacotherapy Issue: Volume 34:Issue 5(2014) Page Start: 440 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. An Open‐Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics. Issue 3 (10th May 2018) Authors: Li, Yan; Wang, Xiaomin; Liu, Liangang; Zhang, Chengyue; Gomez, Diana; Reyes, Josephine; Palmisano, Maria; Zhou, Simon Journal: Clinical pharmacology in drug development Issue: Volume 8:Issue 3(2019) Page Start: 346 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase. (20th March 2022) Authors: Cheng, Yiming; Liu, Liangang; Xue, Yongjun; Zhou, Simon; Li, Yan Journal: Journal of clinical pharmacy and therapeutics Issue: Volume 47:Number 8(2022) Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus. Issue 10 (26th June 2018) Authors: Schafer, Peter H; Ye, Ying; Wu, Lei; Kosek, Jolanta; Ringheim, Garth; Yang, Zhihong; Liu, Liangang; Thomas, Michael; Palmisano, Maria; Chopra, Rajesh Journal: Annals of the rheumatic diseases Issue: Volume 77:Issue 10(2018) Page Start: 1516 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Drug‐Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC‐122) in Healthy Adult Subjects. (6th June 2019) Authors: Ogasawara, Ken; MacGorman, Kimberly; Liu, Liangang; Chen, Jian; Carayannopoulos, Leonidas N.; Zhou, Simon; Palmisano, Maria; Li, Yan Journal: Journal of clinical pharmacology Issue: Volume 59:Number 12(2019) Page Start: 1620 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer. (29th July 2015) Authors: Laille, Eric; Patel, Manish; Jones, Suzanne F.; Burris, Howard A.; Infante, Jeffrey; Lemech, Charlotte; Liu, Liangang; Arkenau, Hendrik‐Tobias Journal: Journal of clinical pharmacology Issue: Volume 55:Number 12(2015:Dec.) Page Start: 1378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator. Issue 5 (23rd September 2020) Authors: Ye, Ying; Gaudy, Allison; Schafer, Peter; Thomas, Michael; Weiss, Daniel; Chen, Nianhang; Liu, Liangang; Xue, Yongjun; Carayannopoulos, Leon; Palmisano, Maria Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 5(2021) Page Start: 471 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects. (15th May 2018) Authors: Li, Yan; Liu, Liangang; Wang, Xiaomin; Zhang, Chengyue; Reyes, Josephine; Hoffmann, Matthew; Palmisano, Maria; Zhou, Simon Journal: Journal of clinical pharmacology Issue: Volume 58:Number 10(2018) Page Start: 1295 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Lenalidomide at Therapeutic and Supratherapeutic Doses Does Not Prolong QTc Intervals in the Thorough QTc Study Conducted in Healthy Men. (20th June 2013) Authors: Chen, Nianhang; Ye, Ying; Liu, Liangang; Reyes, Josephine; Assaf, Mahmoud S.; Kasserra, Claudia; Zhou, Simon; Palmisano, Maria Journal: Basic & clinical pharmacology & toxicology Issue: Volume 113:Number 3(2013) Page Start: 179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pharmacokinetics and safety of apremilast (CC-10004) in subjects with hepatic impairment. (1st January 2014) Authors: Assaf, Mahmoud S.; Laille, Eric; Liu, Liangang; O'Mara, Edward; Wu, Anfan; Palmisano, Maria; Marbury, Thomas C.; Preston, Richard A. Journal: International journal of medical engineering and informatics Issue: Volume 6:Number 2(2014) Page Start: 100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗